title: Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates.
abstract: OBJECTIVE
  To evaluate the responses of serum beta-CTX and osteocalcin in patients who were undergoing treatment with teriparatide or strontium ranelate (SR).
  
  
  METHODS
  We analyzed 14 patients (12 women and 2 men; mean age of 71 years) taking teriparatide, and 13 female patients (mean age of 70 years) taking SR; all the patients having previously been on bisphosphonates. Serum beta-CTX and osteocalcin levels were determined before and after the first and third months of teriparatide treatment and up to the fourth month of treatment with SR.
  
  
  RESULTS
  We observed an initial significant increase in osteocalcin levels during the first month (165%, p = 0.01) followed by a peak of beta-CTX (180%, p = 0.02) after the third month of treatment with teriparatide. An increase in these markers was also observed with SR: 49% in osteocalcin (p = 0.002) and 80% in beta-CTX (p = 0.008).
  
  
  CONCLUSIONS
  SR had a predominantly short-term bone-forming effect in postmenopausal women with osteoporosis previously treated with bisphosphonates in a lesser degree than with teriparatide.
authors.affiliation: Hospital Agamenon Magalhães, Universidade de Pernambuco, Recife, PE, Brasil. belsousamail@hotmail.com <belsousamail@hotmail.com>
authors.forename: Isabel Oliveira de
authors.initials: IO
authors.lastname: Sousa
authors.forename: Erik Trovão
authors.initials: ET
authors.lastname: Diniz
authors.forename: Thyciara Fontenele
authors.initials: TF
authors.lastname: Marques
authors.forename: Luiz
authors.initials: L
authors.lastname: Griz
authors.forename: Mário de Almeida Pereira
authors.initials: Mde A
authors.lastname: Coutinho
authors.forename: Francisco
authors.initials: F
authors.lastname: Bandeira
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D015675:Osteocalcin / Q000097:blood*; D010024:Osteoporosis / Q000097:blood / Q000188:drug therapy*; D010455:Peptides / Q000097:blood; D019379:Teriparatide / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D009942:Organometallic Compounds; D010455:Peptides; D013876:Thiophenes; C081587:strontium ranelate; D015675:Osteocalcin; D019379:Teriparatide